Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Pfizer

Pfizer

Pfizer is an American, multinational pharmaceutical and biotechnology corporation.

Pfizer is an American, multinational pharmaceutical and biotechnology corporation. The company was founded in 1849 by two German immigrants, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891), in New York, New York, United States.

Pfizer has the mission to fund programs that provide public benefit, advance medical care, and can improve patient outcomes. Their researchers preform 25,000 clinical tests everyday for pharmaceutical development and innovations.

Nowadays Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.

Partnerships
BaseLaunch

Pfizer is a partner with the BaseLaunch startup accelerator. The BaseLaunch program receives applications in the fields of therapeutics, diagnostics, digital healthcare, healthcare services, therapeutic platforms, and medical technology.

Insilico Medicine

Insilico Medicine and Pfizer entered into a research collaboration agreement. The agreement allows Pfizer to utilize Insilico Medicine's machine learning technology and Pandomics Discovery Platform to research potential therapeutic targets for a variety of diseases.

AMRA Medical

AMRA Medical and Pfizer's partnership works to investigate body fat distribution and muscle composition in a range of diseases using the UK Biobank registry. The partnership involves the body composition analysis of 100,000 individuals.

CytoReason

Pfizer's partnership with CytoReason gives them access to CytoReason's machine learning platform for drug discovery and development.

XtalPi Inc.

XtalPi Inc. and Pfizer's research collaboration focuses on developing a hybrid physics-and artificial intelligence-powered software platform for accurate molecular modeling of small molecules. The platform is intended to advance both companies capabilities in drug design and solid-form selection.

Distributed Bio

Pfizer and Distributed Bio entered an agreement to license Distributed Bio's SuperHuman Platform to Pfizer. The SuperHuman 2.0 antibody discovery platform will allow Pfizer to utilize the antibody library for screening activities against Pfizer-selected targets.

Domain Therapeutics

Domain Therapeutics and Pfizer entered into a collaboration agreement to asses Domain Therapeutics's bioSensAll platform. The bioSensAll platform defines signaling signatures for each wild-type and mutant receptors. Pfizer aims to use the platform to assess the impact of mutations on different signaling pathways engaged by g protein-coupled receptors.

COVID-19

Pfizer announced that they have identified certain anti-viral compounds that are under development which could be effective in treating the novel coronavirus SARS-CoV-2 responsible for COVID-19. They may enter a partnership with a third party company to screen and identify potential compounds by the end of March, 2020 in order to begin testing in April, 2020.

Pfizer is partnered with BioNTech for co-development and distribution of an mRNA vaccine against SARS-CoV-2 called BNT162.

Timeline

May 4, 2021
Pfizer and BioNTech announces that they hope to file an emergency authorization request for their vaccine for children aged two to 11 in September in the United States.
May 2021
In a UK mix and match study published in the Lancet in May, 830 adults over 50 were randomised to get either the Pfizer or AstraZeneca vaccines first, then the other vaccine later.
April 21, 2021
The preliminary results of a report of 35,000 U.S. women who received either the Moderna or Pfizer shots while pregnant showed their rates of miscarriage, premature births and other complications were comparable to those observed in published reports on pregnant women before the pandemic.
February 25, 2021
Pfizer announces that it has begun studying a third dose of its Covid-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus.
January 11, 2021
Today in healthcare news: EQRx has raised another $500 million, at least 50% of COVID-19 cases spread from people without symptoms, and some evidence that Pfizer's vaccine works against virus mutations.
2021
Pfizer reports its first-quarter 2021 revenues of $14.6 billion, a 42% operational growth.

The first-quarter revenues for the vaccine account for $3.5 billion of total revenues of $14.6 billion.

Although not explicitly addressed in the first-quarter announcement, the company expects the FDA to authorize the Pfizer-BioNTech COVID-19 vaccine within the week for adolescents ages 12 and older.

November 19, 2020
Pfizer and LianBio announce strategic collaboration to expand development of Novel Therapeutics in Greater China.
November 17, 2020
Pfizer launches Covid-19 vaccine delivery trial in four US states.
November 12, 2020
Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

The European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.

November 9, 2020
Pfizer announces that the COVID-19 vaccine it's been developing is 90% effective in people who are not known to already have had the virus.

Products

Acquisitions

Invested in

Patents

Further Resources

Title
Author
Link
Type
Date

Breaking the Rules of Biology to Beat Rare Genetic Disease | Pfizer

Web

Our Science: Pharmaceutical Development | Pfizer | Pfizer

Web

Pfizer's Core Values of Social Responsibility and Philanthropy | Pfizer

Web

What to Know About Coronavirus -- COVID-19 Explained | Pfizer

Web

News

Title
Author
Date
Publisher
Description
By LAURAN NEERGAARD
December 8, 2021
AP NEWS
Pfizer said Wednesday that a booster dose of its COVID-19 vaccine may protect against the new omicron variant even though the initial two doses appear significantly less effective.Pfizer and its partner BioNTech said lab tests showed a booster dose increased by 25-fold the level of so-called neutralizing antibodies against omicron.
By MIKE STOBBE
November 16, 2021
AP NEWS
NEW YORK (AP) -- An influential U.S. advisory panel will discuss expanding eligibility for COVID-19 vaccine booster shots to all adults Friday, a move that could make the shots available nationwide as early as this weekend.
By MATTHEW PERRONE
November 16, 2021
AP NEWS
WASHINGTON (AP) -- Pfizer said Tuesday it is asking U.S. regulators to authorize its experimental pill for COVID-19, setting the stage for a likely launch of the promising therapy in the coming weeks.
By LAURAN NEERGAARD
November 9, 2021
AP NEWS
Pfizer asked U.S. regulators Tuesday to allow boosters of its COVID-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings.
By EMMA H. TOBIN
November 4, 2021
AP NEWS
NEW YORK (AP) -- Are COVID-19 boosters the same as the original vaccines?Yes, COVID-19 boosters use the same recipe as the original shots, despite the emergence of the more contagious delta variant.
SHOW MORE

References

...
Golden logo
By using this site, you agree to our Terms & Conditions.